Evidence map›Paper›PMID 40757239›Full record

ArticleMolecular and clinical oncology2025

A retrospective study of laryngeal squamous cell carcinoma and the significance of the PIK3CA mutation for survival.

Akinobu Kubota, Nobuyuki Bandoh, Takashi Goto, Michihisa Kono, Ryosuke Sato, Shiori Suzuki, Shota Sakaue, Ryuhei Takeda, Shuto Hayashi, Misaki Hayashi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Akinobu KubotaDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Nobuyuki BandohDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Takashi GotoDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Michihisa KonoDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Ryosuke SatoDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Shiori SuzukiDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Shota SakaueDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Ryuhei TakedaDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Shuto HayashiDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Misaki HayashiDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Daisuke ArakiDepartment of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Shogo BabaDepartment of Biology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Yasutaka KatoDepartment of Biology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Miki TakaharaDepartment of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Hiroshi NishiharaKeio Cancer Center, Keio University School of Medicine, Tokyo 160-8582, Japan.
Hajime KamadaDepartment of Neurosurgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to assess clinical features, outcomes and survival in patients with laryngeal squamous cell carcinoma (LSCC) and to associate mutations in cancer-related genes with clinical outcomes. A total of 88 patients with LSCC who underwent curative treatment between April 2008 and May 2024 at Hokuto Hospital (Obihiro, Japan) were included. Mutations in targeted regions of 160 cancer-related genes were analyzed using next-generation sequencing (NGS). LSCC was of glottic type in 65 patients (74%) and supraglottic type in 23 patients (26%). As initial treatment, laryngomicrosurgery, radiotherapy (RT) alone, RT with transoral administration of S-1, concurrent chemoradiotherapy with cisplatin, and total laryngectomy were performed in 6 (7%), 48 (55%), 13 (15%), 8 (9%), and 13 (15%) patients, respectively. Of the 88 patients studied, 25 (28%) died of various causes, including LSCC in 6 (7%), carcinoma other than LSCC in 11 (13%), and other causes in 8 (9%). The 5-year survival rates among all 88 patients with LSCC were 78.7% for overall survival (OS), 91.4% for disease-specific survival (DSS), 77.3% for relapse-free survival (RFS) and 67.5% for laryngectomy-free survival (LFS). OS, DSS, RFS and LFS in patients with early stage LSCC were similar to rates reported in other studies. Actionable mutations were detected in 21 (88%) of 24 patients who underwent NGS-based cancer panel testing.

Indexed as

helical tomotherapylaryngeal squamous cell carcinomanext-generation sequencingPIK3CA mutationtotal laryngectomy

Identifiers

PMID40757239
PMCPMC12311762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.